0HQ1 Stock Chart & Stats
$33.51
$1.35(4.92%)
At close: 4:00 PM EDT
$33.51
$1.35(4.92%)
Day’s Range― - ―
52-Week Range$16.00 - $46.42
Previous CloseN/A
Volume60.00
Average Volume (3M)429.00
Market Cap
$1.71B
Enterprise Value$881.45M
Total Cash (Recent Filing)$325.80M
Total Debt (Recent Filing)$53.97M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Nov 10, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend Yield0.36%
Share Statistics
EPS (TTM)-2.75
Shares Outstanding43,808,390
10 Day Avg. Volume221
30 Day Avg. Volume429
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)0.76
Price to Sales (P/S)2.21
P/FCF Ratio34.28
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue1.44
Enterprise Value/Gross Profit3.26
Enterprise Value/Ebitda-9.12
Forecast
1Y Price Target
$35.00Price Target Upside4.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.52
Revenue Forecast (FY)$639.25M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue And Biorepository MomentumA revenue base with more than half recurring provides greater visibility than project-only demand and supports repeat consumables, services, and biorepository activity. Growth in these businesses can improve customer retention and make future revenue less dependent on individually timed capital projects.
Conservative Balance SheetVery low leverage and a substantial equity cushion reduce refinancing and solvency pressure while preserving flexibility for investment, integration, or operational needs. This financial foundation can help Azenta absorb uneven earnings and pursue strategic initiatives without relying heavily on additional debt.
Expanded GENEWIZ Technology PlatformThe Elegen and SynPlexity transactions broaden GENEWIZ’s capabilities across DNA synthesis, gene assembly, and large-scale screening. These additions can strengthen Azenta’s position in next-generation biologics discovery and support demand from increasingly AI-driven biological design workflows.
Bears Say
Persistent UnprofitabilityNegative operating earnings and a deeply negative net margin show that Azenta is not yet consistently converting revenue into profit. Until operating costs and other charges are better controlled, growth may add limited earnings value and internal funding capacity will remain constrained.
Gross-margin Pressure And Remediation CostsDeclining gross margin in Sample Management Solutions, combined with remediation spending, directly pressures profitability and cash conversion. If automated-store quality and fixed-cost absorption issues persist, the company may need continued investment before this business can deliver sustainably higher margins.
Multiomics Restructuring And Execution DisruptionClosing laboratories and reducing the workforce may eventually improve efficiency, but the transition creates near-term execution risk and substantial charges. Changes to the laboratory footprint can also complicate service continuity, employee retention, and customer relationships while the segment is being reshaped.
Azenta News
0HQ1 FAQ
What was Azenta’s price range in the past 12 months?
Azenta lowest share price was $16.00 and its highest was $46.42 in the past 12 months.
What is Azenta’s market cap?
Azenta’s market cap is $1.71B.
When is Azenta’s upcoming earnings report date?
Azenta’s upcoming earnings report date is Nov 10, 2026 which is in 9 days.
How were Azenta’s earnings last quarter?
Azenta released its earnings results on Aug 04, 2026. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.114 by $0.046.
Is Azenta overvalued?
According to Wall Street analysts Azenta’s price is currently Undervalued.
Does Azenta pay dividends?
Azenta pays a Quarterly dividend of $0.1 which represents an annual dividend yield of 0.36%. See more information on Azenta dividends here
What is Azenta’s EPS estimate?
Azenta’s EPS estimate is 0.11.
How many shares outstanding does Azenta have?
Azenta has 43,808,390 shares outstanding.
What happened to Azenta’s price movement after its last earnings report?
Azenta reported an EPS of $0.16 in its last earnings report, beating expectations of $0.114. Following the earnings report the stock price went up 2.798%.
Which hedge fund is a major shareholder of Azenta?
Currently, no hedge funds are holding shares in GB:0HQ1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Azenta Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.00 (4.45% Upside)
$35.00 (4.45% Upside)
Blogger Sentiment
Bullish
GB:0HQ1 Sentiment 75%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.63%
12-Months-Change
Fundamentals
Return on Equity
-7.56%
Trailing 12-Months
Asset Growth
-7.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Azenta
Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other international markets. Its business is structured into two main reportable segments: Life Sciences Products and Life Sciences Services. The Life Sciences Products division supplies sophisticated automated systems for the cold storage of chemical compounds and biological specimens. This segment also provides crucial equipment for sample preparation and manipulation, along with various consumables and specialized instruments that empower customers to effectively manage samples throughout their entire research and development workflows. Conversely, the Life Sciences Services segment offers a comprehensive suite of programs for sample management, integrated cold chain logistics, cutting-edge informatics, and a range of sample-centric laboratory services. These offerings are vital for propelling scientific research and accelerating drug development. Key services include secure sample banking, advanced genomic sequencing, gene synthesis, laboratory processing, detailed laboratory analysis, biospecimen acquisition, and other essential support functions. Azenta caters to a diverse client base within the life sciences sector, encompassing pharmaceutical companies, biotechnology firms, biorepositories, and academic or private research institutions. Established in 1978, the company, originally known as Brooks Automation, Inc., officially became Azenta, Inc. in December 2021. Its corporate headquarters are located in Chelmsford, Massachusetts.
0HQ1 Company Deck
0HQ1 Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call reflected a cautious but constructive tone: the company delivered a better-than-expected quarter with solid organic revenue growth (9%), sequential profitability improvement (adjusted EBITDA margin up ~610 bps sequentially) and progress on strategic initiatives (AI-enabled biorepository deployment, modular stores, UKBC integration, and B Medical divestiture). However, meaningful near-term headwinds remain — notably gross margin pressure (overall and in Sample Management Solutions), quality remediation costs ($5M–$6M expected), ongoing Sanger secular decline, negative quarterly free cash flow, and a difficult Q4 comp. Management emphasized disciplined execution and a measured outlook. Overall, positives around execution and a stronger outlook are balanced by persistent margin and demand uncertainties.View all GB:0HQ1 earnings summaries0HQ1 Stock 12 Month Forecast
Average Price Target
$35.00
▲(4.45% Upside)